Article
Presented by Georg Bartsch, MD, University of Innsbruck, Austria
Lower-dose abiraterone offers viable alternative to standard-dose for mCRPC
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
Survey: New NMIBC treatments face slow uptake
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
FDA updates in urology: May 2025
NIAGARA: ctDNA analysis highlights durvalumab’s impact in MIBC
Long-term data support radium-223 safety in mCRPC
RCT compares platinum/5-FU, platinum/paclitaxel in high-risk penile cancer